Multiple Myeloma Genomics Initiative (MMGI)
Progressive genome mapping program
In 2005, the MMRF launched the multi-million dollar Multiple Myeloma Genomics Initiative (MMGI), a progressive genome-mapping program. It was designed to significantly advance the biological understanding of the disease and accelerate the development of therapies tailored to DNA alterations in myeloma cells. We are directing efforts to have 500 relapsed and refractory myeloma patients molecularly profiled allowing us to accelerate targeted therapies for specific subgroups. Over time, we aim to profile every myeloma patient.
Myeloma’s most extensive research collaboration
Today the MMGI stands as the most extensive research collaboration ever focused on the genomics of multiple myeloma. Our funding of the project, and our development of a model for collaboration among the Broad Institute, the Translational Genomics Research Institute (Tgen), and leading multiple myeloma experts, has resulted in:
- An invaluable centralized repository of high-quality myeloma genomic information
- Engagement with a research community of nearly 600 registered members
- Open access, high resolution data available to researchers in real-time through the Initiative’s Genomics Portal
- Cutting-edge bioinformatics tools to help analyze and interpret data
Uncovering novel connections
By analyzing samples from our tissue bank, the MMGI has uncovered novel connections between the disease and important molecular targets. We are conducting studies targeting key proteins that might be driving the disease, and engaging with industry partners who have promising molecular compounds that may effectively inhibit these proteins. It has improved the understanding of how multiple myeloma develops, and accelerated our ability to identify specific subtypes and design therapies to treat them.
Research professionals interested in accessing data from the
CoMMpass study should contact the MMRF at